PT3342786T - Anticorpo anti-dll3 - Google Patents

Anticorpo anti-dll3

Info

Publication number
PT3342786T
PT3342786T PT181569740T PT18156974T PT3342786T PT 3342786 T PT3342786 T PT 3342786T PT 181569740 T PT181569740 T PT 181569740T PT 18156974 T PT18156974 T PT 18156974T PT 3342786 T PT3342786 T PT 3342786T
Authority
PT
Portugal
Prior art keywords
dll3 antibody
dll3
antibody
Prior art date
Application number
PT181569740T
Other languages
English (en)
Original Assignee
Chugai Pharmaceutical Co Ltd
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3342786(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Univ Tokyo filed Critical Chugai Pharmaceutical Co Ltd
Publication of PT3342786T publication Critical patent/PT3342786T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
PT181569740T 2010-01-29 2011-01-28 Anticorpo anti-dll3 PT3342786T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010019391 2010-01-29

Publications (1)

Publication Number Publication Date
PT3342786T true PT3342786T (pt) 2021-09-24

Family

ID=44319091

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181569740T PT3342786T (pt) 2010-01-29 2011-01-28 Anticorpo anti-dll3
PT117368126T PT2530091T (pt) 2010-01-29 2011-01-28 Anticorpo anti-dll3

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT117368126T PT2530091T (pt) 2010-01-29 2011-01-28 Anticorpo anti-dll3

Country Status (14)

Country Link
US (3) US9127071B2 (pt)
EP (3) EP3342786B1 (pt)
JP (1) JP5918540B2 (pt)
DK (2) DK3342786T3 (pt)
ES (2) ES2674420T3 (pt)
HR (2) HRP20211444T1 (pt)
HU (2) HUE056313T2 (pt)
LT (2) LT3342786T (pt)
PL (2) PL2530091T3 (pt)
PT (2) PT3342786T (pt)
RS (2) RS57412B1 (pt)
SI (2) SI2530091T1 (pt)
TR (1) TR201806936T4 (pt)
WO (1) WO2011093097A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0910509B8 (pt) * 2008-07-10 2021-05-25 Toray Industries uso do anticorpo, anticorpo e composição farmacêutica
HRP20211444T1 (hr) 2010-01-29 2021-12-24 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antitijelo
CA3050672A1 (en) 2012-02-24 2013-08-29 Abbvie Stemcentrx Llc Dll3-binding antibodies and drug conjugates thereof to treat cancer
WO2013147153A1 (ja) * 2012-03-29 2013-10-03 株式会社未来創薬研究所 抗ｌａｍｐ５抗体およびその利用
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
BR112015019909A2 (pt) 2013-02-22 2017-08-29 Abbvie Stemcentrx Llc Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
US9562099B2 (en) * 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
BR112015022019A2 (pt) 2013-03-14 2017-08-29 Genentech Inc Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
WO2015031541A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
BR112016004073A8 (pt) * 2013-08-28 2018-06-12 Stemcentrx Inc Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3
EP3038644B1 (en) * 2013-08-28 2021-04-07 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
MX2016002799A (es) * 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
WO2015068847A1 (ja) 2013-11-11 2015-05-14 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
WO2015127407A1 (en) 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
CA2956072A1 (en) 2014-07-21 2016-01-28 Bloodworks Antibodies that recognize red blood cell antigens
AR101936A1 (es) 2014-07-31 2017-01-25 Amgen Res (Munich) Gmbh Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
EP3219724A4 (en) 2014-11-11 2018-09-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
HUE054316T2 (hu) 2017-03-29 2021-08-30 Shionogi & Co Gyógyászati készítmény rák kezelésére
KR20200045520A (ko) * 2017-09-07 2020-05-04 오거스타 유니버시티 리서치 인스티튜트, 인크. 프로그래밍된 세포사 단백질 1에 대한 항체
CR20200195A (es) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc Proteínas de unión a antigenos de maduraciòn de celulas b
WO2019111871A1 (en) 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CN118146372A (zh) 2018-05-08 2024-06-07 凡恩世制药(北京)有限公司 抗dll3抗体及其用途
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
AU2019346466A1 (en) * 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN113795262A (zh) * 2019-04-08 2021-12-14 东莞凡恩世生物医药有限公司 人源化抗dll3嵌合抗原受体及其用途
JPWO2021038975A1 (pt) 2019-08-28 2021-03-04
IL296802A (en) 2020-03-31 2022-11-01 Chugai Pharmaceutical Co Ltd A method for the production of multispecific antigen binding molecules
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
CA3193569A1 (en) * 2020-09-28 2022-03-31 Xiaofeng Liu Anti-sclerostin constructs and uses thereof
CA3204731A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Anti-dll3 antibody-drug conjugate
AU2022207708A1 (en) 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CR20240135A (es) * 2021-09-17 2024-05-17 Wuxi Biologics Ireland Ltd Moléculas de unión a d3 y usos de estas
WO2023053272A1 (en) 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
WO2023092082A1 (en) * 2021-11-18 2023-05-25 Bentley Cornelia Antibodies to receptor of advanced glycation end products (rage) and uses thereof
WO2024012524A1 (zh) * 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Ind Co Ltd Semiconductor laser protective circuit
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
DE69836131T3 (de) 1997-04-04 2017-06-14 Millennium Pharmaceuticals, Inc. Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
US20030180784A1 (en) 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
JP4332581B2 (ja) 1998-02-19 2009-09-16 旭化成株式会社 ヒトデルタ−３
JP4139508B2 (ja) 1998-02-19 2008-08-27 旭化成株式会社 ヒトデルター３
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1159284A4 (en) 1999-02-10 2003-10-29 Human Genome Sciences Inc 33 HUMAN SECRETARY PROTEINS
DK2270150T4 (da) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
WO2001012664A2 (en) 1999-08-19 2001-02-22 Chiron Corporation Notch receptor ligands and uses thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2002014358A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Novel secreted proteins and their uses
EP2314686B2 (en) 2000-10-06 2023-06-21 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20050137130A1 (en) 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
EP1594447A2 (en) * 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
EP1642971B1 (en) 2003-06-18 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Fucose transporter
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
CA2633593A1 (en) * 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
CA2637267A1 (en) * 2006-01-16 2007-07-19 Compugen Ltd. Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
EP2078731A4 (en) 2006-10-20 2012-08-01 Forerunner Pharma Res Co Ltd PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
JP5299902B2 (ja) 2007-01-30 2013-09-25 中外製薬株式会社 キメラＦｃγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法
AU2009235467A1 (en) * 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
JP4787295B2 (ja) 2008-07-14 2011-10-05 株式会社トープラ 高強度セルフフォーミングねじによるねじ締結構造体
HRP20211444T1 (hr) 2010-01-29 2021-12-24 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antitijelo
CA3050672A1 (en) * 2012-02-24 2013-08-29 Abbvie Stemcentrx Llc Dll3-binding antibodies and drug conjugates thereof to treat cancer
WO2015127407A1 (en) * 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體

Also Published As

Publication number Publication date
EP3342786A1 (en) 2018-07-04
US20120328624A1 (en) 2012-12-27
US11111311B2 (en) 2021-09-07
ES2889932T3 (es) 2022-01-14
PL2530091T3 (pl) 2018-08-31
RS57412B1 (sr) 2018-09-28
DK3342786T3 (en) 2021-09-27
EP2530091A4 (en) 2013-07-10
PT2530091T (pt) 2018-05-17
PL3342786T3 (pl) 2021-12-20
HRP20180952T1 (hr) 2018-07-27
HUE056313T2 (hu) 2022-02-28
LT3342786T (lt) 2021-10-25
US9127071B2 (en) 2015-09-08
SI2530091T1 (en) 2018-06-29
EP3907242A1 (en) 2021-11-10
RS62387B1 (sr) 2021-10-29
HRP20211444T1 (hr) 2021-12-24
JP5918540B2 (ja) 2016-05-18
EP2530091A1 (en) 2012-12-05
WO2011093097A1 (ja) 2011-08-04
LT2530091T (lt) 2018-06-11
TR201806936T4 (tr) 2018-06-21
EP2530091B1 (en) 2018-04-04
EP3342786B1 (en) 2021-06-23
SI3342786T1 (sl) 2022-01-31
ES2674420T3 (es) 2018-06-29
HUE038962T2 (hu) 2018-12-28
US20150368355A1 (en) 2015-12-24
US20210380715A1 (en) 2021-12-09
JPWO2011093097A1 (ja) 2013-05-30
US20160244530A2 (en) 2016-08-25
DK2530091T3 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
HRP20180952T1 (hr) Anti-dll3 antitijelo
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
HUE040213T2 (hu) Anti-TIM antitest
ZA201209004B (en) Anti-fgfr2 antibodies
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
EP2543730A4 (en) VARIANT OF A CONSTANT ANTIBODY REGION
IL225667A0 (en) A new antigen
HK1194388A1 (zh) 抗缺刻蛋白 抗體
GB201020738D0 (en) Antibodies
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
GB201002238D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201007957D0 (en) Antibody
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
GB201017780D0 (en) Antibody
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies